Johnson Keir, Clegg Stephanie, Alsoof Daniel, Daniels Alan H, Deren Matthew E, Cohen Eric M
Alpert Medical School of Brown University, Providence, RI, USA.
University of Massachusetts Medical Center, Department of Orthopedics and Physical Rehabilitation, Worcester, MA, USA.
Arthroplast Today. 2022 Sep 20;17:198-204.e2. doi: 10.1016/j.artd.2022.07.020. eCollection 2022 Oct.
Prostate cancer (PCa) is a common cancer among men in the United States. While malignancy is a known cause of venous thromboembolism (VTE), little is known about the effect of PCa history on postoperative complications after elective total hip arthroplasty (THA). This study aimed to evaluate the risk of hematologic complications in patients with a history of PCa taking common postoperative anticoagulants.
THA patients were identified through the PearlDiver Mariner database. Patients with a history of PCa were placed in one of the following cohorts based on postoperative anticoagulant prescription: aspirin, warfarin, low-molecular-weight heparin, direct Xa inhibitor, or any anticoagulant. PCa cohorts were matched 1:3 to patients without a history of PCa with the same anticoagulant prescription based on age, gender, and Charlson Comorbidity Index. Postoperative complications were evaluated using multivariable logistic regression.
A total of 74,744 patients that underwent THA were included. PCa patients taking any anticoagulant were found to have increased risk of postoperative deep vein thrombosis (DVT) (odds ratio: 1.25, lower 99% confidence interval: 1.09, upper 99% confidence interval: 1.43, value <.001). PCa patients taking warfarin, low-molecular-weight heparin, and direct Xa inhibitors additionally showed increased risk of postoperative DVT. Patients taking aspirin did not have an increased risk of postoperative DVT.
Our results suggest postoperative aspirin prophylaxis may not increase VTE complication risk when compared to other anticoagulants. Surgeons should be aware that PCa history may be an independent risk factor for VTE, and these patients may benefit from medical optimization.
前列腺癌(PCa)是美国男性中的常见癌症。虽然恶性肿瘤是静脉血栓栓塞(VTE)的已知病因,但关于PCa病史对择期全髋关节置换术(THA)术后并发症的影响知之甚少。本研究旨在评估有PCa病史的患者使用常见术后抗凝剂时发生血液学并发症的风险。
通过PearlDiver Mariner数据库识别THA患者。有PCa病史的患者根据术后抗凝剂处方被纳入以下队列之一:阿司匹林、华法林、低分子量肝素、直接Xa抑制剂或任何抗凝剂。根据年龄、性别和Charlson合并症指数,将PCa队列与无PCa病史且使用相同抗凝剂处方的患者按1:3进行匹配。使用多变量逻辑回归评估术后并发症。
共纳入74744例行THA的患者。发现使用任何抗凝剂的PCa患者术后深静脉血栓形成(DVT)风险增加(优势比:1.25,99%置信区间下限:1.09,99%置信区间上限:1.43,P值<.001)。使用华法林、低分子量肝素和直接Xa抑制剂的PCa患者术后DVT风险也增加。服用阿司匹林的患者术后DVT风险未增加。
我们的结果表明,与其他抗凝剂相比,术后使用阿司匹林预防可能不会增加VTE并发症风险。外科医生应意识到PCa病史可能是VTE的独立危险因素,这些患者可能从医学优化中获益。